Abstract
Background: The effects of anti-dementia drugs on gait performance in Alzheimer disease (AD) are questionable. The objective of this meta-analysis was to examine the effects of anti-dementia drugs on the mean value and the coefficient of variation (CoV) of stride time among patients with AD while taking into account the type of drugs (i.e., acetylcholinesterase inhibitors [AChEIs] versus memantine) and the walking conditions (i.e., single versus dual-task). Methods: An English and French Medline search was conducted in March 2015, with no limit of date, using the Medical Subject Headings terms “pharmaceutical preparations” combined with terms "Pharmaceutical preparations" OR "Therapeutic uses" OR "Drug substitution" OR "Drugs essential" OR "Drugs, Generic" OR "Psychotropic drugs" combined with "Delirium” OR “Dementia” OR “Amnestic” OR “Cognitive disorders" AND "Gait" OR "Gait Ataxia" OR "Gait disorders, Neurologic" OR “Gait apraxia”. Fixed-effects meta-analyses were used to examine anti-dementia drugs-related changes in mean value and CoV of stride time. Results: Of the 66 identified abstracts, 5 (7.6%) were included in the meta-analysis. Inter-group comparison of between-visit change underscored a significant decrease in CoV of stride time (P<0.004) in intervention group compared to control group, whatever the pooled analysis considered, but no significant change in the mean value (P>0.06). Intra-group changes in stride time parameters following the use of anti-dementia drugs showed a significant decrease for memantine (P<0.001) and while pooling AChEIs and memantine (P<0.001) under single task condition. Under dual task condition, only AChEIs improved significantly stride time parameters (P=0.002). Conclusion: Anti-dementia drugs demonstrated a significant improvement of gait performance with specific class effect depending on the walking conditions and on the type of stride time parameters considered.
Keywords: Alzheimer disease, anti-dementia drugs, dual task, gait disorders, meta-analysis, older adults.
Current Alzheimer Research
Title:Anti-dementia drugs-related changes in gait performance while single and dual tasking in patients with Alzheimer disease: a meta-analysis
Volume: 12 Issue: 8
Author(s): O. Beauchet, C. P. Launay, M Montero-Odasso, C Annweiler and G. Allali
Affiliation:
Keywords: Alzheimer disease, anti-dementia drugs, dual task, gait disorders, meta-analysis, older adults.
Abstract: Background: The effects of anti-dementia drugs on gait performance in Alzheimer disease (AD) are questionable. The objective of this meta-analysis was to examine the effects of anti-dementia drugs on the mean value and the coefficient of variation (CoV) of stride time among patients with AD while taking into account the type of drugs (i.e., acetylcholinesterase inhibitors [AChEIs] versus memantine) and the walking conditions (i.e., single versus dual-task). Methods: An English and French Medline search was conducted in March 2015, with no limit of date, using the Medical Subject Headings terms “pharmaceutical preparations” combined with terms "Pharmaceutical preparations" OR "Therapeutic uses" OR "Drug substitution" OR "Drugs essential" OR "Drugs, Generic" OR "Psychotropic drugs" combined with "Delirium” OR “Dementia” OR “Amnestic” OR “Cognitive disorders" AND "Gait" OR "Gait Ataxia" OR "Gait disorders, Neurologic" OR “Gait apraxia”. Fixed-effects meta-analyses were used to examine anti-dementia drugs-related changes in mean value and CoV of stride time. Results: Of the 66 identified abstracts, 5 (7.6%) were included in the meta-analysis. Inter-group comparison of between-visit change underscored a significant decrease in CoV of stride time (P<0.004) in intervention group compared to control group, whatever the pooled analysis considered, but no significant change in the mean value (P>0.06). Intra-group changes in stride time parameters following the use of anti-dementia drugs showed a significant decrease for memantine (P<0.001) and while pooling AChEIs and memantine (P<0.001) under single task condition. Under dual task condition, only AChEIs improved significantly stride time parameters (P=0.002). Conclusion: Anti-dementia drugs demonstrated a significant improvement of gait performance with specific class effect depending on the walking conditions and on the type of stride time parameters considered.
Export Options
About this article
Cite this article as:
Beauchet O., Launay P. C., Montero-Odasso M, Annweiler C and Allali G., Anti-dementia drugs-related changes in gait performance while single and dual tasking in patients with Alzheimer disease: a meta-analysis, Current Alzheimer Research 2015; 12 (8) . https://dx.doi.org/10.2174/1567205012666150710111341
DOI https://dx.doi.org/10.2174/1567205012666150710111341 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Compensating, Controlling, Resigning and Accepting-Older Persons Perception of Physical Decline
Current Aging Science The Effects of Antihypertensive Therapy on Haemostatic Parameters
Current Pharmaceutical Design Neuroprotection and Sex Steroid Hormones: Evidence of Estradiol- Mediated Protection in Hypertensive Encephalopathy
Mini-Reviews in Medicinal Chemistry Cerebrospinal Fluid Proteins in the Diagnosis of Alzheimers Disease
Recent Patents on CNS Drug Discovery (Discontinued) Therapeutic Targeting of the Endoplasmic Reticulum in Alzheimers Disease
Current Alzheimer Research Protein Folding and Misfolding, Endoplasmic Reticulum Stress in Neurodegenerative Diseases: in Trace of Novel Drug Targets
Current Protein & Peptide Science Oxidative Stress in HIV Patients Receiving Antiretroviral Therapy
Current HIV Research Selection of Antithrombotic Therapy in Patients with Atrial Fibrillation and Percutaneous Coronary Intervention
Current Pharmaceutical Design Cognitive Identity in Schizophrenia: Vision, Space, and Body Perception from Prodrome to Syndrome
Current Psychiatry Reviews A Balanced View of Efficacy and Safety of Aspirin in Cardiovascular Diseases
Current Pharmaceutical Design Tau Phosphorylation and Aggregation as a Therapeutic Target in Tauopathies
CNS & Neurological Disorders - Drug Targets Molecular Effects of L-dopa Therapy in Parkinson’s Disease
Current Genomics Natural Products as Promising Drug Candidates for the Treatment of Alzheimer’s Disease: Molecular Mechanism Aspect
Current Neuropharmacology Therapeutic Targets in Prostaglandin E2 Signaling for Neurologic Disease
Current Medicinal Chemistry Drugs and Rhabdomyolysis: From Liver to Kidney
Current Vascular Pharmacology Investigating Serotonergic Function Using Positron Emission Tomography: Overview and Recent Findings
Current Pharmaceutical Design New Pharmacological Approaches to the Cholinergic System: An Overview on Muscarinic Receptor Ligands and Cholinesterase Inhibitors
Recent Patents on CNS Drug Discovery (Discontinued) Hybrid SPECT/CT Imaging in Neurology
Current Radiopharmaceuticals The Renin-Angiotensin System in the Mammalian Central Nervous System
Current Protein & Peptide Science Familial Hypercholesterolemia: Etiology, Diagnosis and New Treatment Options
Current Pharmaceutical Design